Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies

v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies  
Commitments And Contingencies

Note 8 – Commitments and Contingencies

 

a) Finance Lease Obligations

 

In 2016, the Company entered into a capital lease with ING Asset Finance Belgium S.A. (“ING”) to purchase a property located in Belgium for €1.12 million, maturing in May 2031 with implicit interest of 2.62%. As of June 30, 2023, the balance payable was $467,223.

 

The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of June 30, 2023.

 

2023

 

$ 29,362

 

2024

 

$ 58,722

 

2025

 

$ 58,722

 

2026

 

$ 58,723

 

2027

 

$ 58,723

 

Greater than 5 years

 

$ 256,898

 

Total

 

$ 521,150

 

Less: Amount representing interest

 

$ (53,927 )

Present value of minimum lease payments

 

$ 467,223

 

 

 

b) Operating Lease Right-of-Use Obligations

 

As of June 30, 2023, operating lease right-of-use assets and liabilities arising from operating leases were $530,669 and $558,456, respectively. During the six months ended June 30, 2023, cash paid for amounts included for the measurement of lease liabilities was $126,276 and the Company recorded operating lease expense of $127,495. The Company’s weighted average discount rate is 2.53% and the weighted average remaining lease term is 23 months.

 

The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of June 30, 2023.

 

2023

 

$ 141,718

 

2024

 

$ 173,422

 

2025

 

$ 129,643

 

2026

 

$ 101,773

 

2027

 

$ 33,625

 

2028

 

$ 1,304

 

Total Operating Lease Obligations

 

$ 581,485

 

Less: Amount representing interest

 

$ (23,029 )

Present Value of minimum lease payments

 

$ 558,456

 

 

 

The Company’s office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the six months ended June 30, 2023, the Company recognized $33,426 in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows:

 

2023

 

$ 41,416

 

2024

 

$ 32,656

 

Total Operating Lease Liabilities

 

$ 74,072

 

 

 

c) Grants Repayable

 

In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €1.05 million. Per the terms of the agreement, €314,406 of the grant is to be repaid, by installments over the period from June 30, 2014 to June 30, 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6.00% royalty on revenue, is equal to twice the amount of funding received. As of June 30, 2023, the grant balance repayable was $27,294.

 

In 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €605,000. Per the terms of the agreement, €181,500 of the grant is to be repaid by installments over 12 years commencing in 2020. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received. As of June 30, 2023, the grant balance repayable was $109,133.

 

In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €929,433. Per the terms of the agreement, €278,830 of the grant is to be repaid by installments over 15 years commencing in 2022. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received. As of June 30, 2023, the grant balance repayable was $234,378.

 

In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €495,000. Per the terms of the agreement, €148,500 of the grant is to be repaid by installments over 10 years commencing in 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received. As of June 30, 2023, the grant balance repayable was $99,485.

 

As of June 30, 2023, the total grant balance repayable was $470,290 and the payments remaining were as follows:

 

2023

 

$ 50,133

 

2024

 

$ 26,999

 

2025

 

$ 35,178

 

2026

 

$ 42,753

 

2027

 

$ 46,772

 

Greater than 5 years

 

$ 268,455

 

Total Grants Repayable

 

$ 470,290

 

 

d) Long-Term Debt

 

In 2016, the Company entered into a 7-year loan agreement with Namur Invest for €440,000 with a fixed interest rate of 4.85%, maturing in December 2023. As of June 30, 2023, the principal balance payable was $42,553.

 

In 2016, the Company entered into a 15-year loan agreement with ING for €270,000 with a fixed interest rate of 2.62%, maturing in December 2031. As of June 30, 2023, the principal balance payable was $182,670.

 

In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to €1 million with a fixed interest rate of 4.50%, maturing in September 2024. As of June 30, 2023, €1 million had been drawn down under this agreement and the principal balance payable was $382,122.

 

In 2019, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 with a fixed interest rate of 4.80%, maturing in September 2024. As of June 30, 2023, the principal balance payable was $205,545.

 

In 2020, the Company entered into a 10-year loan agreement with Namur Invest for a maximum of €830,000 with fixed interest rate of 4.00%, maturing March 2031. As of June 30, 2023, the principal balance payable was $732,612.

 

In 2021, the Company entered into a 3 ½ year loan agreement with SOFINEX for a maximum of €450,000 with fixed interest rate of 5.00%, maturing June 2025. As of June 30, 2023, the principal balance payable was $368,474.

 

In 2022, the Company entered into a 4 year loan agreement with Namur Invest for a maximum of €1.0 million with fixed interest rate of 6.0%, maturing in July 2026. As of June 30, 2023, the principal balance payable was $973,472.

 

In 2022, the Company entered into a 4-year loan agreement with Namur Invest for a maximum of €500,000 with fixed interest rate of 5.45%, maturing December 2027. As of June 30, 2023, the principal balance payable was $545,888.

 

In June 2023, the Company entered into a 4-year loan agreement with Namur Invest for a maximum of €400,000 with fixed interest rate of 7.0%, maturing June 2027. As of June 30, 2023, €200,000 had been drawn down under this agreement and the principal balance payable was $218,355.

 

As of June 30, 2023, the total balance for long-term debt payable was $3,651,691 and the payments remaining were as follows:

 

2023

 

$ 711,033

 

2024

 

$ 1,228,413

 

2025

 

$ 787,000

 

2026

 

$ 559,176

 

2027

 

$ 304,115

 

Greater than 5 years

 

$ 454,520

 

Total

 

$ 4,044,257

 

Less: Amount representing interest

 

$ (392,566 )

Total Long-Term Debt

 

$ 3,651,691

 

 

e) Collaborative Agreement Obligations

 

In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a three-year research period for a cost to the Company of up to $2.55 million payable over such period. As of June 30, 2023, $510,000 is still to be paid by the Company under this agreement.

 

In 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps ("NETs") in cancer patients with sepsis for a cost to the Company of $449,406. As of June 30, 2023, $449,406 is due by the Company under this agreement.

 

As of June 30, 2023, the total amount to be paid for future research and collaboration commitments was approximately $959,406 and the payments remaining were as follows:

 

2023

 

$ 877,633

 

2024 - 2027

 

$ 81,773

 

Total Collaborative Agreement Obligations 

 

$ 959,406

 

 

f) Other Commitments

 

Volition Vet

 

On October 25, 2019, the Company entered into an agreement with TAMU for provision of in kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest as of such date. As of June 30, 2023, TAMU has a 12.5% equity interest in Volition Vet.

 

Volition Germany

 

On January 10, 2020, the Company, through its wholly-owned subsidiary Belgian Volition, acquired an epigenetic reagent company, Octamer GmbH (“Octamer”), based in Munich, Germany, and hired its founder for his expertise and knowledge to be passed to Company personnel. On March 9, 2020, Octamer was renamed to Volition Germany GmbH (or “Volition Germany”).

 

In connection with the transaction agreement, the Company entered into a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of five years post-closing.

 

As of June 30, 2023, $213 is payable under the 6% royalty agreement on sales to date towards the Company’s aggregate minimum royalty obligation of $120,095.

 

Volition America

 

On November 3, 2020, the Company entered into a professional services master agreement (the “Master Agreement”) with Diagnostic Oncology CRO, LLC (“DXOCRO”) to conduct a pivotal clinical trial and provide regulatory submission and reimbursement related services. On August 8, 2022, the Company and DXOCRO amended and restated the Master Agreement to expand the scope of DXOCRO’s consultant services provided thereunder (the “A&R Master Agreement”). The A&R Master Agreement requires DXOCRO to support development and clinical validation studies for the Company’s Nu.Q® product portfolio in the United States, including by conducting large-scale finding studies across multiple sites in the U.S. using Nu.Q® NETs and Nu.Q® Cancer tests to determine clinical utility in sepsis and non-Hodgkin’s lymphoma. The Company anticipates DXOCRO’s services under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million. The Company’s payment obligations accrue upon delivery of projects under the agreement. The Company may terminate the agreement or any project thereunder upon at least 30 days’ prior written notice. Unless earlier terminated, the A&R Master Agreement terminates on the later of December 31, 2025 or the date upon which all services have been completed. As of June 30, 2023, $428,669 is payable under the A&R Master Agreement, and up to $1,316,023 may be payable by Company in future periods for services rendered.

 

VolitionRx

 

On February 27, 2023, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $356,258 with fixed interest rate of 7.42%, maturing November 2023. As of June 30, 2023, the maximum has been drawn down under this agreement and the principal balance payable was $197,921.

 

g) Legal Proceedings

 

There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

 

h) Commitments in Respect of Corporate Goals and Performance-Based Awards

 

In August 2021 and October 2021 the Compensation Committee of the Board of Directors approved the granting of equity-based awards under the 2015 Plan as well as cash bonuses, vesting upon achievement of certain corporate goals focused around product development and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries.

 

On June 23, 2022, the Compensation Committee of the Board of Directors approved the achievement of all of the remaining outstanding corporate goals related to the awards in August 2021 and October 2021 resulting in the payment of the cash bonus awards and the vesting of the remaining rights to the equity-based awards, which equity-based awards remain subject to time-based vesting in equal installments on each of August 3, 2022 and August 3, 2023 (with the exception of October 4, 2022 and October 4, 2023 for one award) and the continuous service of the award recipient through the applicable vesting date.

 

In October 2022, the Compensation Committee of the Board of Directors approved the granting of RSUs under the 2015 Plan to various employees in exchange for services provided to the Company. These RSUs vest upon the achievement of certain corporate goals focused around product development and commercialization with further time based vesting over three years, and subject to continued service.

 

In October 2022, the Compensation Committee of the Board of Directors approved the granting of RSUs under the 2015 Plan to various employees in exchange for services provided to the Company. These RSUs vest upon the share price closing above $5.00 per share for a minimum of ten consecutive trading days within a period of three years from the date of grant, with further time based vesting in a single installment six months after the timely achievement of the target, if at all, and subject to continued service.

 

h) Commitments in Respect of Corporate Goals and Performance-Based Awards (continued)

 

In October 2022 the Compensation Committee of the Board of Directors approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around product development, manufacturing, financing and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries. Conditional upon the achievement by January 1, 2023 and July 1, 2023 of all specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. As of June 30, 2023, the Company has accrued compensation expense of $1,069,523 in relation to the July 1, 2023 specified corporate goals based on the actual outcomes related to the prescribed performance targets.

 

An aggregate of 1,144,000 RSUs were issued under the 2015 Plan in connection with the October 2022 grants and an aggregate of 1,000,000 stock options and 500,000 RSUs were issued under the 2015 Plan in connection with the August 2021 and October 2021 grants.

 

As of June 30, 2023, the Company has recognized compensation expense of $854,055 in relation to the options that will vest in 2023. The Company has unrecognized compensation expense of $51,995 in relation to such stock options, based on the outcomes related to the prescribed performance targets on the outstanding awards.

 

Total

 

 

Amortized

 

 

Amortized

 

 

Amortized

 

 

Un-Amortized

 

Award

 

 

2023

 

 

2022

 

 

2021

 

 

2023

 

 $

 

 

$

 

 

 $

 

 

$

 

 

$

 

 

969,592

 

 

 

-

 

 

 

580,411

 

 

 

389,181

 

 

 

-

 

 

854,055

 

 

 

223,192

 

 

 

450,090

 

 

 

180,773

 

 

 

51,995

 

 

As of June 30, 2023, the Company has recognized compensation expense of $718,946 in relation to RSUs that will vest in 2023. The Company has unrecognized compensation expense of $134,992 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.

 

Total

 

 

Amortized

 

 

Amortized

 

 

Amortized

 

 

Un-Amortized

 

Award

 

 

2023

 

 

2022

 

 

2021

 

 

2023

 

$

 

 

$

 

 

 

 

$

 

 

$

 

 

822,149

 

 

 

-

 

 

 

493,207

 

 

 

328,942

 

 

 

-

 

 

718,946

 

 

 

188,016

 

 

 

379,191

 

 

 

151,739

 

 

 

134,992

 

 

As of June 30, 2023, the Company has recognized total compensation expense of $724,339 of which $393,663 in relation to RSUs that will vest in 2023, $195,105 in relation to RSUs that will vest in 2024, and $135,571 in relation to RSUs that will vest in 2025. The Company has unrecognized compensation expense of $873,837 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards.

 

Vesting

 

Amortized

 

 

Amortized

 

 

Un-Amortized

 

 Year

 

2023

 

 

2022

 

 

 

 

 

$

 

 

$

 

 

$

 

2023

 

 

259,576

 

 

 

134,087

 

 

 

139,144

 

2024

 

 

130,017

 

 

 

65,088

 

 

 

329,274

 

2025

 

 

88,886

 

 

 

46,686

 

 

 

405,419

 

 

 

 

478,479

 

 

 

245,861

 

 

 

873,837